Moderna (CHIX:0QFD) Debt-to-Asset : 0.12 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:0QFD Moderna Inc CHIX:0QFD
57 GF Score
Price €118.00
GF Value €22.09
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Moderna Debt-to-Asset?

Moderna CHIX:0QFD 57 Debt-to-Asset is 0.12 as of Jun. 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 57/100 and a GF Value™ of €22.09 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Moderna's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €45 Mil. Moderna's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €1,072 Mil. Moderna's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was €9,514 Mil. Moderna's debt to asset for the quarter that ended in Jun. 2026 was 0.12.

Moderna  (CHIX:0QFd) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Moderna Debt-to-Asset Related Terms

Moderna Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Moderna's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna Debt-to-Asset Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.05 0.07 0.05 0.11

Moderna Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.11 0.11 0.12

CHIX:0QFD vs BNTX, INSM, INCY: Debt-to-Asset Comparison

For the Biotechnology subindustry, Moderna's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Moderna's Debt-to-Asset falls into.


CHIX:0QFD
57GF Score
Moderna Inc CHIX:0QFD
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Moderna's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(35.868 + 1078.602) / 10536.652
=0.11

Moderna's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(45.136 + 1071.98) / 9514.148
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.12 mean?
Moderna (CHIX:0QFD) has a Debt-to-Asset of 0.12 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Moderna and its competitors.
Is Moderna's Debt-to-Asset too high?
Moderna's current Debt-to-Asset is 0.12. Overall, Moderna has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's Debt-to-Asset compare to BNTX and INSM?
Moderna's Debt-to-Asset of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Moderna and its competitors. Moderna's current Debt-to-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €22.09, compared to a current price of €118.00 — trading 434.2% above its estimated fair value. The current Debt-to-Asset is 0.12. Moderna's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current Debt-to-Asset is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (CHIX:0QFD) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €118.00 is trading 434.2% above its estimated GF Value™ of €22.09. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for CHIX:0QFD:

  • Debt-to-Asset: 0.12
  • GF Value™: €22.09 vs. price of €118.00 (434.2% above fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
57GF Score

Get the complete analysis for CHIX:0QFD

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€118.00
Price
€22.09
GF Value